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Kansas City, Missouri; Hartford, Connecticut; and Durham, North CarolinaThe lack of standardized reporting of the magnitude of ischemia on noninvasive imaging contributes
to variability in translating the severity of ischemia across stress imaging modalities. We identiﬁed
the risk of coronary artery disease (CAD) death or myocardial infarction (MI) associated with $10%
ischemic myocardium on stress nuclear imaging as the risk threshold for stress echocardiography
and cardiac magnetic resonance. A narrative review revealed that $10% ischemic myocardium on
stress nuclear imaging was associated with a median rate of CAD death or MI of 4.9%/year
(interquartile range: 3.75% to 5.3%). For stress echocardiography, $3 newly dysfunctional segments
portend a median rate of CAD death or MI of 4.5%/year (interquartile range: 3.8% to 5.9%). Although
imprecisely delineated, moderate-severe ischemia on cardiac magnetic resonance may be indicated
by $4 of 32 stress perfusion defects or $3 dobutamine-induced dysfunctional segments. Risk-based
thresholds can deﬁne equivalent amounts of ischemia across the stress imaging modalities, which
will help to translate a common understanding of patient risk on which to guide subsequent
management decisions. (J Am Coll Cardiol Img 2014;7:593–604) ª 2014 by the American College of
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CAD = coronary artery
disease
CMR = cardiac magnetic
resonance
MI = myocardial infarction
NHLBI = National Heart,
Lung, and Blood Institute
NIH = National Institutes
of Health
OMT = optimal medical
therapy
PCI = percutaneous
coronary intervention
SIHD = stable ischemic
heart disease
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594Stress imaging is commonly used to evaluate sus-
pected myocardial ischemia in patients with symp-
toms suggestive of stable ischemic heart disease
(SIHD). The evidence to support the use of several
stress imaging modalities is substantial and has
been synthesized in recent appropriate use criteria
and clinical practice guidelines (1–3). The published
evidence base for stress nuclear imaging and echo-
cardiography as effective tools for diagnosis of cor-
onary artery disease (CAD) and risk stratiﬁcation
is extensive, and there is growing evidence sup-
porting the role of stress cardiac magnetic resonance
(CMR).
However, the optimal evaluation and treatment
algorithm following stress imaging has not been
clearly deﬁned. Although diagnostic coronary angio-
graphy is commonly preceded by stress testing,
nearly two-thirds of patients manifest no obstructiveCardiov
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(4,5). Before elective percutaneous coronary
intervention (PCI), less than one-half of pa-
tients have had a stress test in the previous 90
days (6). These data illustrate the lack of ac-
curacy and consistency in clinical practice in
the appropriate use of stress imaging to guide
the management of patients with SIHD
(1,7,8).
One noteworthy gap in the current evidence
base is the absence of established comparable
categories of the magnitude of ischemia across
noninvasive imaging modalities. The lack of
standardized grading and inconsistency in
reporting of the extent and severity of ischemia
in clinical practice may contribute to the wide
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For this report, experts in the ﬁeld of stress car-
diac imaging were enlisted to propose a consensus of
comparable deﬁnitions for moderate-severe ischemia
for stress nuclear imaging (myocardial perfusion
single-photon emission computed tomography and
positron emission tomography), echocardiography,
and CMR (wall motion or perfusion). The cut
points for moderate-severe ischemia were estab-
lished using the selected, published evidence for
each modality correlating stress imaging results with
risk of CAD death or myocardial infarction (MI).
The aim of this review was to propose a deﬁnition
for equivalent amounts of ischemia across the stress
imaging modalities for patients with SIHD who
have preserved left ventricular function, which will
help to translate a common understanding of patient
risk on which to guide subsequent management
decisions.
Targeting Moderate-Severe Ischemia
Most SIHD revascularization strategy trials have
included patients with ischemia on stress testing or
typical angina with at least 1 coronary stenosis
amenable to revascularization, although only a
subset of enrolled patients reported stress test results
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Figure 1. Projected CAD Event Rates
A theoretical plot of the relationship between abnormal stress imaging ﬁnd-
ings and projected CAD events is shown. The lines include the average pro-
jected CAD event rate and 95% conﬁdence intervals. As the stress imaging
abnormalities become more extensive and severe, the projected CAD event
rate increases. Conversely, for subsets with normal or mildly abnormal studies,
the event rates are low. CAD ¼ coronary artery disease.
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595(Clinical Outcomes Utilizing Revascularization
and Aggressive Drug Evaluation) trial ischemia re-
quirements included a minimum of 1 segment with
a perfusion defect or typical ischemic ST-segment
changes with exercise (11), resulting in a represen-
tation of patients ranging from those with mild to
moderate ischemia on imaging (13). Given the
potential representation of patients with less
extensive and severe ischemia in the COURAGE
trial, a lingering question is whether SIHD trial
outcomes would have been different if the
COURAGE or National Institutes of Health/
National Heart, Lung, and Blood Institute (NIH/
NHLBI)-sponsored BARI 2D (Bypass Angioplasty
Revascularization Investigation in Type 2 Diabetes)
trials enrolled a larger proportion of higher-risk
patients with moderate or severe ischemia (11,12).
There is limited evidence to guide treatment for
these higher-risk patients.
Figure 1 shows the projected relationship between
the underlying abnormal stress imaging ﬁndings and
projected CAD events. For stress imaging, the
extent of ischemia is directly related to the rate of
subsequent CAD events. Yearly CAD event rates
generally range fromw1% for normal stress imaging
ﬁndings to as high as 10% for severely abnormal
studies. Several observational studies have also
shown that the degree of relative risk reduction with
treatment is related to the amount of ischemia
observed on noninvasive imaging (14–18).
Challenges in Uniformly Quantifying Ischemia
Across the Stress Imaging Modalities
A major challenge in deﬁning comparable risk-
based thresholds for moderate-severe ischemia
across modalities is that there are notable differences
in the various imaging techniques regarding what is
assessed, interpreted, and quantiﬁed. Although it is
recommended that all stress imaging techniques use
the standardized 17-segment model for quantiﬁca-
tion of wall motion and perfusion (19), the 17th
segment (i.e., apical cap) is not separately assessed
on stress echocardiography or CMR myocardial
perfusion imaging. There are also differences in the
numerical scale used to classify the severity of
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596These conceptual differences may promote a vari-
able relationship between a threshold for moderate-
severe ischemia and a given associated CAD event
rate.
Thus, it remains unlikely that absolute thresholds
of percentage ischemic myocardium could be
deﬁned similarly across the stress imaging modal-
ities, resulting in the need for an alternative
approach. Therefore, we sought to identify those
parameters on each imaging modality that portend
similarly elevated risk levels and to use these to
develop comparable thresholds to guide future care
decisions (Fig. 2).
There is an important consideration that risk
alone should not be the sole determinant of deﬁning
the potential for therapeutic risk reduction. The
purpose of the current review is to identify compa-
rable risk groups across stress imaging modalities.
For some patient subsets, information on the extent
and severity of ischemia must be balanced with
correlative information on the burden of comor-
bidity and CAD as well as the presence of under-
lying left ventricular dysfunction. As such, for our
review, we have limited the focus of our discussion
to patients with preserved systolic function.
Because of variable reporting of prognosis by the
severity of ischemia, we could not perform a sys-
tematic review. In some cases, data were reported
only as survival curves with variable follow-up and
without inclusion of the number at risk or average
duration of follow-up, included revascularization as
an endpoint, reported hazard ratios only, or deﬁned
ischemia as a dichotomous variable (yes/no). For
these reasons, we could not systematically collectRisk-Based Comparisons
ical approach to comparing levels of moderate-severe ischemia
stress imaging modalities is used to deﬁne similar CAD event rates.
ion as in Figure 1.clinical outcome data for moderate-severe ischemia
and the current review should be considered a
narrative that highlights selected published evidence
with available rates of CAD death or MI in
moderate-severe ischemia. Contributing authors
also identiﬁed additional data on prognosis with
moderate-severe ischemia for the 3 stress imaging
modalities. Importantly, we did not use standard-
ized search terms or independently judge study
quality; this review represents the opinions of the
investigators and is not a systematized synthesis of
all available evidence.
The search strategies in MEDLINE included
coronary disease prognosis and the speciﬁc imaging
modality (stress myocardial perfusion imaging,
echocardiography, CMR wall motion or perfusion
imaging). Selected event rates were derived from the
published literature by initially focusing on the rate
of CAD death or MI in the nuclear cardiology
literature. We selected a variety of published registry
reports with available event data and follow-up
duration in the subset of patients with moderate-
severe ischemia. The event data were obtained
from crude rates or reported survival rates. There are
several reports on prognosis from selected registries
that report similar event rates by moderate-severe
ischemia. However, we did not include event data
from duplicate patient series.
Published Evidence of Elevated Risk Associated
With Moderate-Severe Ischemia
For stress nuclear imaging data, we examined the
extensive prognostic evidence reported from multi-
ple sites, for different radioisotopes, and for positron
emission tomography and single-photon emission
computed tomography to deﬁne CAD event risk
(22). In the nuclear cardiology literature, a threshold
of $10% ischemic myocardium has been applied to
denote high-risk status (14–16,22–26). Initial
prognostic reports used a summed difference score
(summed stress score  summed rest score) to
provide an estimate of the overall magnitude of
ischemia, combining both extent of ischemia
(i.e., number of myocardial segments) and severity
(i.e., depth of the defect) (26–29). Recent reports
have relied on percentage myocardium as a summary
metric to enhance clinical understanding of the
complexity of ﬁndings of ischemia. The percentage
ischemic myocardium may be measured using
semiquantitative ([summed difference score/68
(maximal segmental score ¼ 4)] $ 100 ¼ percentage
ischemic myocardium) or computer-based quanti-
tative techniques (percentage ischemic myocardium)
Figure 3. Risk of CAD Death or MI for Moderate-Severe Ischemia
The median rates of CAD death or MI (%/year) on the basis of moderate-severe
ischemia on stress nuclear myocardial perfusion imaging and stress echocar-
diography are shown. This narrative review highlights selected published evi-
dence of rates of CAD death or MI for stress nuclear imaging and
echocardiography; the dashed lines show the interquartile range of the CAD
event rates (per year). The expected rate of CAD death or MI across all of the
stress imaging modalities is w4% to 6%/year. There are limitations to our
median estimate, including that this was not a systematic review because of
differential sample size, variable length of follow-up, and the use of mortality
only or revascularization as an endpoint. MI ¼ myocardial infarction; other
abbreviation as in Figure 1.
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597(22). There may be variability when using quanti-
tative or semiquantitative approaches for interpre-
tation such that a threshold of 10% from 1
method may be slightly higher or lower using an
alternative technique. However, in the nuclear car-
diology literature, a threshold of $10% of the
myocardium has been reported across a number
of prognostic series to denote moderate-severe
ischemia (14–16,22–26). For clinical practice pur-
poses, the risk associated with a threshold of
w10% ischemic myocardium has been reported and
forms the target cut point for our cross-modality
estimation of the risk of CAD death or MI
(1,16,22,27,30).
A review of the published literature reveals that
the median rate of CAD death or MI for patients
with $10% ischemic myocardium was w4.9%/year
(interquartile range: w3.7% to 5.3%/year) (Fig. 3)
(16,27,30–34). For stress nuclear imaging, the range
of CAD event rates was from as low as 2.3%/year
(32) to as high as 6.9%/year (34). These ﬁndings of
a w5% annual CAD event risk are consistent with
recent SIHD trials reporting a similar rate of yearly
endpoints (11,12).
Although not derived from the rigors of a clinical
trial setting, observational evidence suggests that the
threshold of $10% ischemic myocardium may be
used as a benchmark from which to deﬁne treatment
effectiveness (14–16). Observational evidence in-
dicates that medical therapy alone is associated
with a reduced risk of death as compared with
revascularization for patients with less extensive and
severe ischemia (i.e., <10% of the myocardium);
conversely, patients with $10% ischemic myocar-
dium had a reduced risk of CAD and all-cause
death with coronary revascularization as compared
with medical therapy (14,15). Selection bias is
operational in observational evidence whereby
patients with signiﬁcant comorbidity would be less
likely to undergo revascularization despite their
ischemic risk, thus rendering the comparison of
medical therapy and revascularization for patients
with $10% ischemia as hypothesis generating.
Importantly, in a secondary analysis of 468 patients
in the COURAGE trial with site-interpreted
moderate-severe ischemia, randomization to PCI
with optimal medical therapy (OMT) did not result
in improved death or MI-free survival when
compared with OMT alone (p ¼ 0.72) (13).
The published research on stress echocardiogra-
phy commonly indicates that the wall motion score
index includes a very high risk threshold of >1.5 or
>1.7 (17,35–39) with an annual CAD mortality rate
of >7% and a signiﬁcantly elevated hazard for deathof 6 (36,37). This high-risk wall motion score index
is rarely observed in clinical practice. We sought to
deﬁne clinically useful criteria at a lower level to
deﬁne a threshold of moderate ischemia. Applying a
threshold of 3 or more ischemic segments, the
hazard for CAD events was elevatedw4-fold when
compared with patients with normal stress echo-
cardiographic results (35,40,41). The available evi-
dence using a deﬁnition of $3 newly dysfunctional
segments revealed an interquartile range from 3.8%
to 5.9% (median 4.5%) for annual risk of CAD
death or MI (Fig. 3) (17,35,39,41–49). For stress
echocardiography, the CAD event rates ranged from
as low as 2.8%/year (47) to as high as 9.4%/year (45).
This result overlaps with the ﬁndings of moderate-
severe ischemia with stress nuclear imaging.
A review of the published literature on stress
CMR does not reveal consistent documentation of
higher-risk versus lower-risk ischemia but more
often a dichotomous reporting of normal/abnormal
or ischemia (yes/no). However, in one report, a
subset of very-high-risk patients with >5 of 16
segments with perfusion defects (including ischemic
and ﬁxed) had a risk of a CAD event ofw14%/year
(50). Similarly, a subset of high-risk patients with 2
to 3 vessel perfusion defects had a hazard ratio that
was elevated 4.5-fold to 7.0-fold that of patients
without perfusion defects (51). There are also
several patient series reporting that patients with
events had an average of 4 of 16 segments with
Figure 4.
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598stress perfusion defects or dysfunctional segments as
compared with <2 abnormal segments for event-
free survivors (50,52,53). Moreover, the unad-
justed hazard for CAD death or MI was elevated
w1.2 for every segment with an ischemic perfusion
defect when compared with patients with a normal
stress perfusion study who have an observed CAD
event rate of w1%/year, suggesting that patients
with >3 ischemic perfusion defects would have an
annual risk of CAD death or MI of w5% (52,53).
A similar relative hazard per ischemic defect or
dysfunctional segment was reported from a larger
series of 908 patients undergoing stress perfusion
CMR (54).
Speciﬁc data with regard to prognosis associa-
ted with dobutamine-induced dysfunctional seg-
ments have been reported. The relative hazard for
events was elevated 7.1-fold for 3 to 5 dobutamine-
induced wall motion abnormalities when compared
with a w1% event rate for patients with normal
stress CMR (51). Similarly, a relative hazard of 1.2-
fold per dysfunctional segment at stress was re-
ported, which would equate an annual CAD event
rate of w5% for $3 abnormal segments (52,53).
Thus, a reasonable deﬁnition for moderate-severe
ischemia with stress CMR (annual rate of CAD
death or MI of w5%) may be $4 of 32 stress
perfusion defects ($2 of 16 segments) or $3
dobutamine-induced dysfunctional segments (of 16
segments), with CAD event rates similar to those of
stress nuclear imaging and echocardiography.Year
(CAD Death/MI)
≥
Deﬁnitions of Moderate-Severe Ischemia
le multimodality estimates of moderate-severe ischemia using risk-
esholds of CAD death or MI rates of 4% to 6%/year. CMR ¼ cardiac
resonance; other abbreviations as in Figures 1 and 3.Although differences exist in interpretation of
ischemia across the modalities, the overall prog-
nostic ﬁndings reveal that qualitative or quantitative
measures can be deﬁned that identify overlap in the
annual rates of CAD death or MI of w5%/year
(Fig. 4). It remains likely that the threshold
requirement of moderate-severe ischemia may allow
for greater harmonization in the estimated risk of
CAD events in patients with SIHD.
Consideration of Ancillary High-Risk Markers
We considered revising the criteria for moderate-
severe ischemia by including additional high-risk
qualiﬁers using left ventricular function or volume
measurements in addition to other modality-speciﬁc
measures (such as strain, scarring, edema, or tran-
sient ischemic dilation of the left ventricle). There is
added value when multiple parameters are combined
during the same scan. For example, the presence or
absence of myocardial scarring or edema assessed
during the same scan adds to the information
derived from perfusion and wall motion analyses
(55). Data on the impact of combining these
markers on prognosis and therapeutic decision
making and outcome, however, are lacking. Our
proposed criteria do not distinguish exercise and
pharmacological stress and do not incorporate pa-
tient clinical risk or functional capabilities that
would affect the anticipated risk of CAD events.
There was considerable discussion about the
use of imaging-based criteria alone without inclu-
sion of ancillary markers. One argument was put
forth that simpler is better. The Duke Treadmill
Score integrates 3 parameters into an estimation of
5-year CAD mortality (56). Although additional
exercise parameters have been reported in the peer-
reviewed literature, the novelty of the Duke
Treadmill Score is its parsimony and ease of use.
Ultimately, it was believed that the use of a simple
criterion would be more reliably applied in clinical
practice and the data regarding prognosis are less
robust when additional factors are included. Ideally,
this report could serve as the starting point for the
establishment of stress imaging criteria to be applied
clinically. This would then form the basis for further
revisions that may reﬁne and integrate important
clinical and stress parameters that improve the pre-
cision of CAD risk estimates and the generalizability
of the ﬁndings to varying patient subsets. Impor-
tantly, clinicians should use our thresholds as an
initial guide to estimated risk. Inclusion of additional
clinical, stress testing, or imaging parameters may
further reﬁne estimates for the individual patient.
Table 1. National Institutes of Health/National Heart, Lung,
and Blood Institute–Sponsored ISCHEMIA Trial Criteria for
Moderate-Severe Ischemia
Nuclear
Perfusion
Echocardiographic
Wall Motion
Cardiac Magnetic
Resonance Perfusion
or Wall Motion
$10% ischemic
myocardium
$3 of 16 segments
with stress-
induced
hypokinesis
or akinesis*
$4 of 32 stress perfusion
defects ($2 of
16 segments)
or
$3 dobutamine-induced
dysfunctional segments
(out of 16 segments)
*The one exception to the characterization of ischemic wall motion change is
that when segments change from akinetic to dyskinetic during stress in the
absence of demonstration of a biphasic response, this is considered a
nonspeciﬁc response rather than an ischemic response.
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599Study limitations. The extent to which we cannot
consistently identify the prognosis of moderate-
severe ischemia from the published literature ex-
empliﬁes the limitations of our current knowledge.
The development of more quantitative methods
for determining perfusion defect or dysfunctional
segmental analysis could help deﬁne risk and
guide decisions about treatment. Moreover, the
development of easily deﬁned categories of risk
may further promote quality-based treatment and
performance metrics for laboratory standards. The
prognostic signiﬁcance of noninvasive testing dif-
fers on the basis of the population in which it is
applied. For example, the risk in younger or
exercising patients differs from that of older or
functionally impaired patients. The prevalence of
prior MI or revascularization can also alter the
CAD event risk estimates. We attempted to nar-
row the width of expected CAD event rates by
focusing on patients with SIHD who had
moderate-severe ischemia and preserved left ven-
tricular function. The sample size and length of
follow-up would further contribute variability to
the CAD risk estimates. The smaller sample sizes
for stress echocardiography and CMR (e.g., me-
dian sample sizes of 1,737 and 503, respectively)
may add variability to the CAD event rates when
compared with the larger stress nuclear series
(median sample size: 5,845).
There are also challenges in the reproducibility of
physician-interpreted moderate-severe ischemia
(57). Reproducibility is affected by reader expertise,
equipment, image quality, and other factors. We
anticipate greater variability in the reproducibility of
moderate-severe ischemia when a subjective inter-
pretation is used.
Historically, varied analytical approaches have
been applied in prognostic series to handle the
subsets of patients who undergo coronary revascu-
larization during follow-up. Patients who undergo
early revascularization (e.g., #90 days) are excluded
from analysis in some cases but are censored at the
time of the procedure in other cases (28,43). The
rationale for the censoring of patients who undergo
early revascularization is that the procedure is
believed to affect CAD survival. In this case, the
CAD event rates reﬂect a medical strategy. More
recent series do not use this method of censoring for
revascularization because recent trials failed to show
a clinical beneﬁt from coronary revascularization
when compared with OMT (11,12).
Importantly, these factors inﬂuence the precision
of our estimate. However, we believe that the
attempt to impose rigor in the ﬁeld of stress CADimaging can prompt a greater emphasis on stan-
dardized approaches to image interpretation. We
propose comparable risk-based deﬁnitions for
moderate-severe ischemia that may help to translate
a common understanding of patient risk on which
to guide subsequent management decisions. Our
deﬁnitions are formed on the basis of a number of
assumptions, including that the stress imaging
protocols, interpretation, and reporting are consis-
tent with imaging society standards.
Future Comparative Trial Evidence
In 2012, the NIH/NHLBI-sponsored ISCHEMIA
(International Study of Comparative Health
Effectiveness With Medical and Invasive Ap-
proaches) trial began enrolling patients with
moderate-severe ischemia on stress nuclear imag-
ing, echocardiography, or CMR. The ISCHEMIA
eligibility criteria for moderate-severe ischemia
are detailed in Table 1 and correspond to those
discussed in this report. The primary aim of the
ISCHEMIA trial is to test the hypothesis that
among patients with moderate-severe ischemia on
stress imaging, a routine early invasive strategy
with coronary angiography followed by optimal
revascularization plus OMT is superior to an
initial conservative strategy of OMT alone, with
angiography and revascularization reserved for
those who fail to respond to medical therapy. The
primary endpoint is a composite of incident car-
diovascular death or MI over w4 years of follow-
up. The ISCHEMIA trial will aid in identifying
patients who may beneﬁt from coronary angiog-
raphy and revascularization, with the trial results
affecting the lives of the nearly 10 million patients
who undergo stress imaging each year.
Current evidence indicates that substantial
equipoise exists with regard to the decision to refer
Figure 5. Case Examples
(A) (i) Illustrative case of moderate ischemia with stress myocardial perfusion SPECT. Regadenoson stress (upper rows)/rest (lower rows)
Tc-99m sestamibi SPECT images show moderate reduction of perfusion in the distal, mid, and basal inferior wall. Semiquantitative visual
analysis (lower right polar maps) reveals 3 abnormal segments at stress with a total score of 7 and normal rest scores. The summed dif-
ference score is 7, representing 10% of the myocardium. (ii) Quantitative analysis of the case shown in i. Stress polar maps (middle column)
reveal a perfusion defect (black area) on stress images (top) and normal rest images (middle). The TPD at stress is 11% and at rest is zero,
indicating an ischemic TPD of 11%.
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common belief to the contrary in the cardiology
community. On the basis of 9 published reports
from 51 sites (N ¼ 5,833), the rate of referral from
stress nuclear imaging to coronary angiography in
patients with moderate-severe ischemia was only35% to 65% (58–66). Contemporary data from
the NIH/NHLBI SPARC (Study of Myocardial
Perfusion and Coronary Anatomy Imaging Roles
in CAD), a 40-center multimodality registry
of 3,019 patients enrolled between 2006 and
2008, revealed that only 42% of patients with
Figure 5. Continued
(B) Illustrative case of moderate ischemia with stress echocardiography. Apical views from an exercise stress echocardiogram show moderate
ischemia. Regional wall motion is normal at rest. At peak stress, wall motion abnormalities (severe hypokinesis) are observed in 3 segments:
mid anterior, apical anterior, and apical lateral segments (arrows). See Online Videos 1, 2, 3, and 4. (C) Illustrative case of moderate ischemia
with stress cardiac magnetic resonance perfusion imaging. The top row shows stress perfusion imaging, and the bottom row shows late
gadolinium enhancement imaging of infarction. In both rows, basal short-axis locations are on the left, mid short-axis locations are in the
middle, and distal short-axis locations are on the right. Note the spatial extent of the stress perfusion defect involving the basal anteroseptal
(subendocardial) and inferoseptal (subendocardial and subepicardial), mid anteroseptal (subendocardial and subepicardial), and distal septal
(subendocardial and subepicardial) walls. There are 7 subsegments of 32 demonstrated abnormal stress perfusion defects. None of these
subsegments demonstrated evidence of infarction by late gadolinium enhancement imaging. This case illustrates a patient with moderate
ischemia without infarction in the left anterior descending territory. SPECT ¼ single-photon emission computed tomography; TPD ¼ total
perfusion deﬁcit.
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601moderate-severe ischemia were referred for coro-
nary angiography (63).
Conclusions
On the basis of a selected review of the published
literature, comparable CAD event rates (rate of
CAD death or MI of w5%/year) for patients with
SIHD who have moderate-severe ischemia can be
identiﬁed for those undergoing stress nuclear im-
aging, echocardiography, or CMR. An example of
each of the imaging modalities using the proposed
deﬁnition for moderate-severe ischemia is illustratedin Figure 5 (see Online Videos 1, 2, 3, and 4
for stress echocardiography example). Deﬁning
comparable risk-based thresholds for moderate-
severe ischemia across the different stress imaging
modalities will help to translate a common under-
standing of patient risk and guide management de-
cisions. These risk-based thresholds should be
applied only when standardized protocols and inter-
pretation are used during stress imaging. Deﬁnitive
guidance on the therapeutic effectiveness of an
angiographic-guided strategy for patients with
moderate-severe ischemia will be derived from
ongoing clinical trials, such as the ISCHEMIA trial.
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602Moreover, we put forth a simple criterion that
we believe could be easily applied in clinical
practice. We also identiﬁed limitations to the
development of comparable deﬁnitions. We hope
that this report will serve as a starting point and
that further revisions will ensue to improve the
precision of the CAD risk estimate and the
generalizability of the ﬁndings to varying patient
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